In a report released today, Joanne Wuensch from BMO Capital maintained a Buy rating on Glaukos (NYSE: GKOS), with a price target of $42. The company’s shares closed yesterday at $37.77.
According to TipRanks.com, Wuensch is a 4-star analyst with an average return of 9.8% and a 69.0% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Irhythm Technologies, Stryker Corporation, and Becton Dickinson.
Glaukos has an analyst consensus of Strong Buy, with a price target consensus of $39.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $44.76 and a one-year low of $23.08. Currently, Glaukos has an average volume of 596.8K.
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Glaukos Corp. is an ophthalmic medical device company, which engages in the development and commercialization of products and procedures designed to transform the treatment of glaucoma. Its micro invasive glaucoma surgery procedures are designed to reduce intraocular eye pressure by improving aqueous outflow through the natural physiologic pathway.
